Clinical aspects of PCSK9
Abstract Proprotein convertase subtilisin kexin type 9 (PCSK9) is a circulating protein that impairs LDL clearance by promoting the LDL receptor (LDLR) degradation. PCSK9 has emerged as a new pharmacological target for hypercholesterolemia, and different PCSK9 inhibitors are now evaluated in clinica...
Saved in:
| Published in | Atherosclerosis Vol. 216; no. 2; pp. 258 - 265 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
Amsterdam
Elsevier Ireland Ltd
01.06.2011
Elsevier |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Abstract Proprotein convertase subtilisin kexin type 9 (PCSK9) is a circulating protein that impairs LDL clearance by promoting the LDL receptor (LDLR) degradation. PCSK9 has emerged as a new pharmacological target for hypercholesterolemia, and different PCSK9 inhibitors are now evaluated in clinical trials. Here, we propose an overview of the clinical perspectives of PCSK9. First, we describe the clinical features of patients with PCSK9 mutations, and how these variations impact the cardiovascular risk. Then, we extensively discuss the potential role of circulating PCSK9 as a new biomarker of lipid metabolism. Indeed, many studies conducted in healthy and type 2 diabetic patients have tested the association of circulating PCSK9 with LDL-cholesterol as well as with multiple metabolic parameters. The overall picture of the clinical relevance of circulating PCSK9 is complicated by the effect of nutritional status and hypolipidemic drugs such as statins, fibrates, ezetimibe on plasma PCSK9 concentrations. Finally, we present a brief overview of the available therapeutic strategies to inhibit PCSK9. |
|---|---|
| AbstractList | Abstract Proprotein convertase subtilisin kexin type 9 (PCSK9) is a circulating protein that impairs LDL clearance by promoting the LDL receptor (LDLR) degradation. PCSK9 has emerged as a new pharmacological target for hypercholesterolemia, and different PCSK9 inhibitors are now evaluated in clinical trials. Here, we propose an overview of the clinical perspectives of PCSK9. First, we describe the clinical features of patients with PCSK9 mutations, and how these variations impact the cardiovascular risk. Then, we extensively discuss the potential role of circulating PCSK9 as a new biomarker of lipid metabolism. Indeed, many studies conducted in healthy and type 2 diabetic patients have tested the association of circulating PCSK9 with LDL-cholesterol as well as with multiple metabolic parameters. The overall picture of the clinical relevance of circulating PCSK9 is complicated by the effect of nutritional status and hypolipidemic drugs such as statins, fibrates, ezetimibe on plasma PCSK9 concentrations. Finally, we present a brief overview of the available therapeutic strategies to inhibit PCSK9. Proprotein convertase subtilisin kexin type 9 (PCSK9) is a circulating protein that impairs LDL clearance by promoting the LDL receptor (LDLR) degradation. PCSK9 has emerged as a new pharmacological target for hypercholesterolemia, and different PCSK9 inhibitors are now evaluated in clinical trials. Here, we propose an overview of the clinical perspectives of PCSK9. First, we describe the clinical features of patients with PCSK9 mutations, and how these variations impact the cardiovascular risk. Then, we extensively discuss the potential role of circulating PCSK9 as a new biomarker of lipid metabolism. Indeed, many studies conducted in healthy and type 2 diabetic patients have tested the association of circulating PCSK9 with LDL-cholesterol as well as with multiple metabolic parameters. The overall picture of the clinical relevance of circulating PCSK9 is complicated by the effect of nutritional status and hypolipidemic drugs such as statins, fibrates, ezetimibe on plasma PCSK9 concentrations. Finally, we present a brief overview of the available therapeutic strategies to inhibit PCSK9. |
| Author | Costet, Philippe Le May, Cédric Cariou, Bertrand |
| Author_xml | – sequence: 1 fullname: Cariou, Bertrand – sequence: 2 fullname: Le May, Cédric – sequence: 3 fullname: Costet, Philippe |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24281369$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/21596380$$D View this record in MEDLINE/PubMed https://hal.science/hal-03013330$$DView record in HAL |
| BookMark | eNqNkUFr2zAUx8VoWdNuH2CXkUsZO9h9z5Jt-bBCCVtbGuig7fkhK09UmWNnUlLot59Mshx6KgIJxE9_PX7_U3HUDz0LcY6QI2B1sczN5pnDEG037j7mBSDmoHJA_UFMUNdNhkqrIzEBKDBrsIQTcRrjEgBUjfqjOCmwbCqpYSK-zDrfe2u6qYlrtps4Hdz09-zhrvkkjp3pIn_en2fi6dfPx9lNNr-_vp1dzTNbQr3JXMGuNZWDspR1bQtpVKtto3TdomRXa1exVeBQGgfY2LRK56oWFq1DUxbyTHzf5T6bjtbBr0x4pcF4urma03gHElBKCS-Y2G87dh2Gv1uOG1r5aLnrTM_DNpKuEUAiNIn8sSNtkhQDu0M0Ao0iaUlvRNIokkBREpnef93_tG1XvDi8_m8uAed7wMSkzwXT25Rx4FShUVbjINc7jpPDF8-BovXcW174kHzTYvDvHunyTZLdd_eHXzkuh23oU1GEFAsCehjbH8vH0UmVHP4DG_2ucA |
| CitedBy_id | crossref_primary_10_1007_s13346_013_0161_z crossref_primary_10_1016_j_ijcard_2016_01_194 crossref_primary_10_1016_j_pharmthera_2018_02_002 crossref_primary_10_1111_dom_12819 crossref_primary_10_3892_ijmm_2012_1072 crossref_primary_10_3945_jn_116_235069 crossref_primary_10_1007_s00059_013_3913_0 crossref_primary_10_1136_gutjnl_2018_318155 crossref_primary_10_1002_ptr_8260 crossref_primary_10_1016_S1957_2557_13_70530_3 crossref_primary_10_1139_cjpp_2023_0223 crossref_primary_10_3390_ijms231810221 crossref_primary_10_1016_j_mce_2012_06_007 crossref_primary_10_1016_j_jid_2020_11_013 crossref_primary_10_1371_journal_pone_0162414 crossref_primary_10_1016_j_cca_2019_04_067 crossref_primary_10_3390_ijms22115880 crossref_primary_10_2174_1389557518666180423111442 crossref_primary_10_1038_hr_2016_38 crossref_primary_10_1016_j_hjc_2016_03_002 crossref_primary_10_1038_s12276_022_00757_5 crossref_primary_10_1016_j_jsbmb_2014_06_007 crossref_primary_10_5551_jat_32615 crossref_primary_10_17816_clinpract8370_75 crossref_primary_10_1042_CS20150193 crossref_primary_10_1007_s11239_016_1364_1 crossref_primary_10_2217_clp_12_24 crossref_primary_10_1007_s40262_018_0670_5 crossref_primary_10_1016_j_phrs_2018_06_004 crossref_primary_10_1161_JAHA_115_002806 crossref_primary_10_1517_13543776_2012_667402 crossref_primary_10_1155_2019_7284767 crossref_primary_10_1186_s12967_015_0452_x crossref_primary_10_1016_j_diabet_2020_01_003 crossref_primary_10_1016_j_jacbts_2016_06_007 crossref_primary_10_1016_j_ijcard_2015_05_150 crossref_primary_10_1016_j_abb_2016_03_008 crossref_primary_10_1371_journal_pone_0210808 crossref_primary_10_1371_journal_pone_0072113 crossref_primary_10_1146_annurev_med_111212_144716 crossref_primary_10_1186_1479_5876_12_103 crossref_primary_10_1007_s00011_020_01382_6 crossref_primary_10_1007_s11255_020_02547_2 crossref_primary_10_1016_j_atherosclerosis_2012_10_032 crossref_primary_10_1016_j_cca_2015_10_033 crossref_primary_10_1161_ATVBAHA_118_311903 crossref_primary_10_1016_j_clinthera_2013_06_019 crossref_primary_10_1016_j_acvd_2022_10_004 crossref_primary_10_1016_j_bbrc_2024_150187 crossref_primary_10_1016_j_atherosclerosis_2014_04_001 crossref_primary_10_1053_j_ajkd_2013_02_359 crossref_primary_10_1186_s13104_021_05723_4 crossref_primary_10_1016_j_pharmthera_2013_04_012 crossref_primary_10_1161_ATVBAHA_114_303617 crossref_primary_10_1111_1753_0407_12064 crossref_primary_10_1517_14728214_2014_976553 crossref_primary_10_2217_clp_13_55 crossref_primary_10_1080_17460441_2020_1704728 crossref_primary_10_1016_j_ijcard_2014_07_057 crossref_primary_10_1016_j_numecd_2014_10_015 crossref_primary_10_2174_1871530320666200213114138 crossref_primary_10_1038_nrd3699 crossref_primary_10_1080_1061186X_2022_2092622 crossref_primary_10_1007_s40262_018_0669_y crossref_primary_10_1186_1756_6614_7_4 crossref_primary_10_1002_mnfr_201400366 crossref_primary_10_1016_j_atherosclerosis_2015_01_012 crossref_primary_10_1016_j_atherosclerosis_2016_08_007 crossref_primary_10_3109_07853890_2015_1042908 crossref_primary_10_1016_j_atherosclerosis_2019_08_020 crossref_primary_10_1007_s11745_015_4099_4 crossref_primary_10_1016_j_arteri_2013_10_008 crossref_primary_10_1002_clc_22252 crossref_primary_10_1016_j_atherosclerosis_2013_08_028 crossref_primary_10_1186_1471_2261_14_121 crossref_primary_10_1016_j_jacl_2016_09_015 crossref_primary_10_1016_j_atherosclerosis_2019_11_010 crossref_primary_10_1007_s15027_012_0083_6 crossref_primary_10_3390_jcm11051373 crossref_primary_10_1016_j_cca_2014_10_044 crossref_primary_10_1155_2014_926087 crossref_primary_10_1186_1476_511X_13_188 crossref_primary_10_1016_j_atherosclerosis_2017_04_010 crossref_primary_10_1016_j_fsi_2016_07_013 crossref_primary_10_1016_j_febslet_2013_02_027 crossref_primary_10_1161_CIRCULATIONAHA_114_011697 crossref_primary_10_1016_j_cca_2014_01_043 crossref_primary_10_1016_j_jacl_2016_10_005 crossref_primary_10_1016_S1773_035X_22_00251_9 crossref_primary_10_1194_jlr_M033969 crossref_primary_10_1517_14712598_2015_984682 crossref_primary_10_2459_JCM_0000000000000360 crossref_primary_10_1080_17512433_2017_1263565 crossref_primary_10_1007_s11883_015_0491_z crossref_primary_10_1038_s41598_017_00499_9 crossref_primary_10_1177_1074248414539562 crossref_primary_10_18632_oncotarget_12471 crossref_primary_10_1016_j_cca_2022_11_018 crossref_primary_10_1007_s40618_015_0310_y crossref_primary_10_1016_j_hjc_2019_04_001 crossref_primary_10_1016_j_diabet_2017_07_009 crossref_primary_10_1161_ATVBAHA_115_306032 crossref_primary_10_1016_j_atherosclerosissup_2012_10_021 crossref_primary_10_1242_dmm_022277 crossref_primary_10_1186_1476_511X_11_123 crossref_primary_10_1186_1471_2261_14_192 crossref_primary_10_1016_j_atherosclerosis_2017_04_023 crossref_primary_10_1177_2040622320924569 crossref_primary_10_1016_j_cca_2020_12_013 crossref_primary_10_1038_mt_2011_260 crossref_primary_10_2174_1570161117666190121102323 crossref_primary_10_1080_08998280_2017_11929514 crossref_primary_10_1007_s40261_013_0129_2 crossref_primary_10_1016_S1957_2557_19_30044_6 crossref_primary_10_2174_1568026619666190809094203 crossref_primary_10_1016_j_atherosclerosis_2011_07_098 crossref_primary_10_1038_nrcardio_2014_84 crossref_primary_10_1016_S1957_2557_15_30074_2 crossref_primary_10_1097_CRD_0000000000000025 crossref_primary_10_1016_j_atherosclerosis_2012_07_036 crossref_primary_10_1016_j_gene_2020_145310 crossref_primary_10_1074_jbc_M112_394023 |
| Cites_doi | 10.1002/humu.20882 10.1074/jbc.M708098200 10.1093/hmg/ddi128 10.1016/j.abb.2007.11.009 10.1194/jlr.M800027-JLR200 10.1016/S0149-2918(03)80281-3 10.1126/science.1125884 10.1074/jbc.C700095200 10.1371/journal.pone.0010682 10.1074/jbc.M409699200 10.1016/j.abb.2003.09.011 10.1016/j.bbrc.2007.07.029 10.1073/pnas.0805434105 10.1194/jlr.M008144 10.1194/jlr.C600025-JLR200 10.1161/01.ATV.0000204337.81286.1c 10.1016/j.febslet.2008.02.038 10.1016/j.str.2007.04.004 10.1111/j.1463-1326.2010.01229.x 10.1073/pnas.0409736102 10.1161/ATVBAHA.108.181586 10.1042/CS20070150 10.1210/en.2006-0098 10.1016/j.bbrc.2008.04.004 10.1073/pnas.0712064105 10.1194/jlr.P009860 10.1074/jbc.M109.052407 10.1016/j.jacc.2005.01.051 10.1373/clinchem.2009.128645 10.1371/journal.pone.0001043 10.1194/jlr.M700437-JLR200 10.1074/jbc.M702027200 10.1086/507488 10.1038/nsmb1235 10.1073/pnas.0903849106 10.1152/ajpendo.00166.2007 10.1086/500615 10.1194/jlr.M300203-JLR200 10.1016/j.atherosclerosis.2009.02.012 10.1056/NEJMoa054013 10.1016/j.atherosclerosis.2007.05.003 10.1210/en.2008-1281 10.1186/1476-511X-7-22 10.1007/s00439-003-1071-9 10.1074/jbc.M705831200 10.1161/01.ATV.0000133684.77013.88 10.1136/jmg.2006.038356 10.1042/BJ20070664 10.1161/ATVBAHA.109.194191 10.1038/ng1161 10.1373/clinchem.2007.091280 10.1002/hep.22354 10.1002/humu.21348 10.1373/clinchem.2009.129759 10.1186/1471-2350-7-66 10.1016/j.atherosclerosis.2006.10.003 10.1073/pnas.0703402104 10.1016/j.atherosclerosis.2010.04.015 10.1210/jc.2009-0141 10.1172/JCI29383 10.1194/jlr.M900273-JLR200 10.1016/j.bbrc.2009.10.138 10.1021/bi7016359 10.1373/clinchem.2007.099747 10.1161/01.ATV.0000190668.94752.ab 10.1016/j.amjcard.2007.02.057 10.1074/jbc.M701634200 10.1161/CIRCGENETICS.108.828467 10.1515/CCLM.2009.032 10.1016/j.atherosclerosis.2009.06.023 10.1373/clinchem.2009.126987 10.1161/01.ATV.0000134621.14315.43 10.1016/j.bbrc.2008.07.106 10.1161/01.ATV.0000255311.26383.2f 10.1002/humu.9383 10.1074/jbc.M508582200 10.1161/ATVBAHA.110.220988 10.1073/pnas.0501652102 10.1161/ATVBAHA.110.214130 10.1016/j.atherosclerosis.2010.09.027 10.1210/jc.2009-1952 10.1074/jbc.M808802200 |
| ContentType | Journal Article |
| Copyright | Elsevier Ireland Ltd 2011 Elsevier Ireland Ltd 2015 INIST-CNRS Copyright © 2011 Elsevier Ireland Ltd. All rights reserved. Distributed under a Creative Commons Attribution 4.0 International License |
| Copyright_xml | – notice: Elsevier Ireland Ltd – notice: 2011 Elsevier Ireland Ltd – notice: 2015 INIST-CNRS – notice: Copyright © 2011 Elsevier Ireland Ltd. All rights reserved. – notice: Distributed under a Creative Commons Attribution 4.0 International License |
| DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 1XC |
| DOI | 10.1016/j.atherosclerosis.2011.04.018 |
| DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic Hyper Article en Ligne (HAL) |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1879-1484 |
| EndPage | 265 |
| ExternalDocumentID | oai_HAL_hal_03013330v1 10_1016_j_atherosclerosis_2011_04_018 21596380 24281369 S0021915011003601 1_s2_0_S0021915011003601 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 23N 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAXKI AAXUO ABBQC ABFNM ABJNI ABLJU ABMAC ABMZM ABOCM ABXDB ACDAQ ACGFS ACIUM ACRLP ADBBV ADEZE AEBSH AEKER AENEX AEVXI AEXQZ AFCTW AFFNX AFJKZ AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AIEXJ AIKHN AITUG AJOXV AJRQY AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 EBS EFJIC EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEB HMK HMO HVGLF HZ~ IHE J1W J5H K-O KOM L7B M27 M41 MO0 N9A NCXOZ O-L O9- OAUVE OA~ OK1 OL0 OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSZ T5K WUQ X7M Z5R ZGI ZXP ~G- ~KM 0SF AAIAV ABLVK ABYKQ AHPSJ AJBFU EFLBG LCYCR ZA5 08R AAUGY ABPIF IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 1XC |
| ID | FETCH-LOGICAL-c507t-f2efba6f055377c23a4b8c9487b13ef78f6ec40f13af019c9c95ff6b0dbf1a523 |
| IEDL.DBID | AIKHN |
| ISSN | 0021-9150 |
| IngestDate | Tue Oct 15 15:51:20 EDT 2024 Fri Oct 25 05:24:25 EDT 2024 Thu Sep 26 19:07:21 EDT 2024 Sat Sep 28 07:48:31 EDT 2024 Sun Oct 22 16:05:35 EDT 2023 Fri Feb 23 02:28:07 EST 2024 Tue Oct 15 14:34:00 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | PCSK9 Hypercholesterolemia Lipoprotein Statin LDL Metabolic diseases Lipids Cardiovascular disease Hyperlipoproteinemia Statin derivative Cholesterol Vascular disease Lipoprotein LDL Atherosclerosis Dyslipemia Antilipemic agent |
| Language | English |
| License | CC BY 4.0 Copyright © 2011 Elsevier Ireland Ltd. All rights reserved. Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c507t-f2efba6f055377c23a4b8c9487b13ef78f6ec40f13af019c9c95ff6b0dbf1a523 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
| ORCID | 0000-0002-7554-792X 0000-0002-1580-8040 |
| PMID | 21596380 |
| PQID | 871003109 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | hal_primary_oai_HAL_hal_03013330v1 proquest_miscellaneous_871003109 crossref_primary_10_1016_j_atherosclerosis_2011_04_018 pubmed_primary_21596380 pascalfrancis_primary_24281369 elsevier_sciencedirect_doi_10_1016_j_atherosclerosis_2011_04_018 elsevier_clinicalkeyesjournals_1_s2_0_S0021915011003601 |
| PublicationCentury | 2000 |
| PublicationDate | 2011-06-01 |
| PublicationDateYYYYMMDD | 2011-06-01 |
| PublicationDate_xml | – month: 06 year: 2011 text: 2011-06-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Amsterdam |
| PublicationPlace_xml | – name: Amsterdam – name: Ireland |
| PublicationTitle | Atherosclerosis |
| PublicationTitleAlternate | Atherosclerosis |
| PublicationYear | 2011 |
| Publisher | Elsevier Ireland Ltd Elsevier |
| Publisher_xml | – name: Elsevier Ireland Ltd – name: Elsevier |
| References | Marduel, Carrie, Sassolas (bib0165) 2010; 31 Mayne, Raymond, Chaplin (bib0445) 2007; 361 Dubuc, Chamberland, Wassef (bib0100) 2004; 24 Naoumova, Tosi, Patel (bib0180) 2005; 25 Fan, Yancey, Qiu (bib0320) 2008; 47 Abboud, Karhunen, Lutjohann (bib0250) 2007; 2 Tarugi, Averna, Di (bib0255) 2007; 195 Jeu, Cheng (bib0400) 2003 Scartezini, Hubbart, Whittall, Cooper, Neil, Humphries (bib0230) 2007; 113 Lagace, Curtis, Garuti (bib0080) 2006; 116 Gupta, Fisker, Asselin (bib0430) 2010; 5 Langhi, Le May, Gmyr (bib0280) 2009; 390 Ni, Di, Condra (bib0440) 2010 McNutt, Kwon, Chen, Chen, Horton, Lagace (bib0275) 2009; 284 Grefhorst, McNutt, Lagace, Horton (bib0285) 2008; 49 Troutt, Alborn, Cao, Konrad (bib0395) 2009; 51 Persson, Cao, Stahle (bib0130) 2010; 30 Dubuc, Tremblay, Pare (bib0315) 2010; 51 Cariou, Ouguerram, Zair (bib0260) 2009; 29 Timms, Wagner, Samuels (bib0175) 2004; 114 Hallman, Srinivasan, Chen, Boerwinkle, Berenson (bib0215) 2007; 100 Careskey, Davis, Alborn, Troutt, Cao, Konrad (bib0360) 2008; 49 Zhao, Tuakli-Wosornu, Lagace (bib0270) 2006; 79 Pisciotta, Oliva, Cefalu (bib0195) 2005; 186 Cui, Ju, Yang (bib0300) 2010; 213 Shan, Pang, Zhang, Murgolo, Lan, Hedrick (bib0045) 2008; 375 Lambert, Ancellin, Charlton (bib0340) 2008; 54 Verges, Costet, Duvillard, Brindisi, Krempf, Cariou (bib0295) 2010; 53 Lakoski, Lagace, Cohen, Horton, Hobbs (bib0305) 2009; 94 Alborn, Cao, Careskey (bib0330) 2007; 53 Norata, Garlaschelli, Grigore (bib0245) 2010; 208 Rashid, Curtis, Garuti (bib0065) 2005; 102 Langhi, Le May, Kourimate (bib0120) 2008; 19 Tosi, Toledo-Leiva, Neuwirth, Naoumova, Soutar (bib0160) 2007; 194 Chan, Piper, Cao (bib0435) 2009; 106 Galman, Matasconi, Persson, Parini, Angelin, Rudling (bib0145) 2007; 293 Berge, Ose, Leren (bib0380) 2006; 26 Baass, Dubuc, Tremblay (bib0310) 2009; 55 Chan, Hamilton, Rye (bib0385) 2010; 12 Zaid, Roubtsova, Essalmani (bib0010) 2008; 48 Niesen, Bedi, Lopez (bib0405) 2008; 470 Lambert, Jarnoux, Pineau (bib0350) 2006; 147 Zhang, Lagace, Garuti (bib0050) 2007; 282 Brown, Goldstein, Biomedicine (bib0210) 2006; 311 McNutt, Lagace, Horton (bib0085) 2007; 282 Poirier, Mayer, Benjannet (bib0040) 2008; 283 Fisher, Lo, Pandit (bib0075) 2007; 282 Humphries, Neely, Whittall (bib0325) 2009; 55 Maxwell, Soccio, Duncan, Sehayek, Breslow (bib0105) 2003; 44 Lakoski, Xu, Vega (bib0375) 2010; 95 Abifadel, Rabes, Devillers (bib0155) 2009; 30 Cariou, Le Bras, Langhi (bib0335) 2010; 211 Roubtsova, Munkonda, Awan (bib0055) 2011; 31 Mbikay, Sirois, Mayne (bib0410) 2009; 584 Huang, Fornage, Lloyd-Jones, Wei, Boerwinkle, Liu (bib0205) 2009; 2 Ouguerram, Chetiveaux, Zair (bib0355) 2004; 24 Frank-Kamenetsky, Grefhorst, Anderson (bib0420) 2008; 105 Benjannet, Rhainds, Essalmani (bib0005) 2004; 279 Piper, Jackson, Liu (bib0035) 2007; 15 Cunningham, Danley, Geoghegan (bib0025) 2007; 14 Le May, Kourimate, Langhi (bib0015) 2009; 29 Mayne, Dewpura, Raymond (bib0390) 2008; 7 Li, Tumanut, Gavigan (bib0090) 2007; 406 Welder, Zineh, Pacanowski, Troutt, Cao, Konrad (bib0370) 2010; 51 Mayer, Poirier, Seidah (bib0095) 2008 Humphries, Whittall, Hubbart (bib0185) 2006; 43 Cohen, Boerwinkle, Mosley, Hobbs (bib0200) 2006; 354 Hsu, Teng, Ko (bib0240) 2009; 47 Schmidt, Beyer, Bensch (bib0290) 2008; 370 Costet, Cariou, Lambert (bib0115) 2006; 281 Sun, Eden, Tosi (bib0170) 2005; 14 Hampton, Knuth, Li, Harris, Lesley, Spraggon (bib0030) 2007; 104 Kourimate, Le, Langhi (bib0125) 2008; 283 Li, Dong, Park, Lee, Chen, Liu (bib0110) 2009; 284 Kourimate, Chetiveaux, Jarnoux, Lalanne, Costet (bib0415) 2009; 206 Kwon, Lagace, McNutt, Horton, Deisenhofer (bib0070) 2008; 105 Browning, Horton (bib0140) 2010; 51 Allard, Amsellem, Abifadel (bib0190) 2005; 26 Evans, Beil (bib0235) 2006; 7 Abifadel, Varret, Rabes (bib0150) 2003; 34 Chen, Ballantyne, Gotto, Tan, Willerson, Marian (bib0220) 2005; 45 Graham, Lemonidis, Whipple (bib0425) 2007; 48 Kotowski, Pertsemlidis, Luke (bib0225) 2006; 78 Maxwell, Fisher, Breslow (bib0060) 2005; 102 Fasano, Cefalu, Di (bib0265) 2007; 27 Chan, Lambert, Barrett, Rye, Ooi, Watts (bib0345) 2009; 55 Costet, Hoffmann, Cariou, Guyomarc’h Delasalle (bib0365) 2010; 212 Persson, Galman, Angelin, Rudling (bib0135) 2009; 150 Naureckiene, Ma, Sreekumar (bib0020) 2003; 420 Berge (10.1016/j.atherosclerosis.2011.04.018_bib0380) 2006; 26 Roubtsova (10.1016/j.atherosclerosis.2011.04.018_bib0055) 2011; 31 Cariou (10.1016/j.atherosclerosis.2011.04.018_bib0260) 2009; 29 Baass (10.1016/j.atherosclerosis.2011.04.018_bib0310) 2009; 55 Troutt (10.1016/j.atherosclerosis.2011.04.018_bib0395) 2009; 51 Poirier (10.1016/j.atherosclerosis.2011.04.018_bib0040) 2008; 283 Lagace (10.1016/j.atherosclerosis.2011.04.018_bib0080) 2006; 116 Kourimate (10.1016/j.atherosclerosis.2011.04.018_bib0415) 2009; 206 Benjannet (10.1016/j.atherosclerosis.2011.04.018_bib0005) 2004; 279 Piper (10.1016/j.atherosclerosis.2011.04.018_bib0035) 2007; 15 Maxwell (10.1016/j.atherosclerosis.2011.04.018_bib0105) 2003; 44 Langhi (10.1016/j.atherosclerosis.2011.04.018_bib0280) 2009; 390 Lambert (10.1016/j.atherosclerosis.2011.04.018_bib0340) 2008; 54 Galman (10.1016/j.atherosclerosis.2011.04.018_bib0145) 2007; 293 Ni (10.1016/j.atherosclerosis.2011.04.018_bib0440) 2010 Mayer (10.1016/j.atherosclerosis.2011.04.018_bib0095) 2008 Abifadel (10.1016/j.atherosclerosis.2011.04.018_bib0150) 2003; 34 Fasano (10.1016/j.atherosclerosis.2011.04.018_bib0265) 2007; 27 Humphries (10.1016/j.atherosclerosis.2011.04.018_bib0185) 2006; 43 Scartezini (10.1016/j.atherosclerosis.2011.04.018_bib0230) 2007; 113 Langhi (10.1016/j.atherosclerosis.2011.04.018_bib0120) 2008; 19 Niesen (10.1016/j.atherosclerosis.2011.04.018_bib0405) 2008; 470 Frank-Kamenetsky (10.1016/j.atherosclerosis.2011.04.018_bib0420) 2008; 105 Zhang (10.1016/j.atherosclerosis.2011.04.018_bib0050) 2007; 282 Timms (10.1016/j.atherosclerosis.2011.04.018_bib0175) 2004; 114 Norata (10.1016/j.atherosclerosis.2011.04.018_bib0245) 2010; 208 Dubuc (10.1016/j.atherosclerosis.2011.04.018_bib0315) 2010; 51 Fisher (10.1016/j.atherosclerosis.2011.04.018_bib0075) 2007; 282 Abboud (10.1016/j.atherosclerosis.2011.04.018_bib0250) 2007; 2 Ouguerram (10.1016/j.atherosclerosis.2011.04.018_bib0355) 2004; 24 Maxwell (10.1016/j.atherosclerosis.2011.04.018_bib0060) 2005; 102 Cariou (10.1016/j.atherosclerosis.2011.04.018_bib0335) 2010; 211 Chan (10.1016/j.atherosclerosis.2011.04.018_bib0345) 2009; 55 Kwon (10.1016/j.atherosclerosis.2011.04.018_bib0070) 2008; 105 Humphries (10.1016/j.atherosclerosis.2011.04.018_bib0325) 2009; 55 McNutt (10.1016/j.atherosclerosis.2011.04.018_bib0085) 2007; 282 Chen (10.1016/j.atherosclerosis.2011.04.018_bib0220) 2005; 45 Verges (10.1016/j.atherosclerosis.2011.04.018_bib0295) 2010; 53 Lakoski (10.1016/j.atherosclerosis.2011.04.018_bib0375) 2010; 95 Hampton (10.1016/j.atherosclerosis.2011.04.018_bib0030) 2007; 104 Allard (10.1016/j.atherosclerosis.2011.04.018_bib0190) 2005; 26 Mayne (10.1016/j.atherosclerosis.2011.04.018_bib0390) 2008; 7 Abifadel (10.1016/j.atherosclerosis.2011.04.018_bib0155) 2009; 30 Marduel (10.1016/j.atherosclerosis.2011.04.018_bib0165) 2010; 31 Persson (10.1016/j.atherosclerosis.2011.04.018_bib0130) 2010; 30 Huang (10.1016/j.atherosclerosis.2011.04.018_bib0205) 2009; 2 Chan (10.1016/j.atherosclerosis.2011.04.018_bib0385) 2010; 12 Gupta (10.1016/j.atherosclerosis.2011.04.018_bib0430) 2010; 5 Tarugi (10.1016/j.atherosclerosis.2011.04.018_bib0255) 2007; 195 Lambert (10.1016/j.atherosclerosis.2011.04.018_bib0350) 2006; 147 Zaid (10.1016/j.atherosclerosis.2011.04.018_bib0010) 2008; 48 Le May (10.1016/j.atherosclerosis.2011.04.018_bib0015) 2009; 29 Shan (10.1016/j.atherosclerosis.2011.04.018_bib0045) 2008; 375 Costet (10.1016/j.atherosclerosis.2011.04.018_bib0365) 2010; 212 Cohen (10.1016/j.atherosclerosis.2011.04.018_bib0200) 2006; 354 McNutt (10.1016/j.atherosclerosis.2011.04.018_bib0275) 2009; 284 Rashid (10.1016/j.atherosclerosis.2011.04.018_bib0065) 2005; 102 Li (10.1016/j.atherosclerosis.2011.04.018_bib0090) 2007; 406 Browning (10.1016/j.atherosclerosis.2011.04.018_bib0140) 2010; 51 Grefhorst (10.1016/j.atherosclerosis.2011.04.018_bib0285) 2008; 49 Tosi (10.1016/j.atherosclerosis.2011.04.018_bib0160) 2007; 194 Zhao (10.1016/j.atherosclerosis.2011.04.018_bib0270) 2006; 79 Hsu (10.1016/j.atherosclerosis.2011.04.018_bib0240) 2009; 47 Graham (10.1016/j.atherosclerosis.2011.04.018_bib0425) 2007; 48 Chan (10.1016/j.atherosclerosis.2011.04.018_bib0435) 2009; 106 Welder (10.1016/j.atherosclerosis.2011.04.018_bib0370) 2010; 51 Mbikay (10.1016/j.atherosclerosis.2011.04.018_bib0410) 2009; 584 Li (10.1016/j.atherosclerosis.2011.04.018_bib0110) 2009; 284 Naureckiene (10.1016/j.atherosclerosis.2011.04.018_bib0020) 2003; 420 Cui (10.1016/j.atherosclerosis.2011.04.018_bib0300) 2010; 213 Costet (10.1016/j.atherosclerosis.2011.04.018_bib0115) 2006; 281 Naoumova (10.1016/j.atherosclerosis.2011.04.018_bib0180) 2005; 25 Careskey (10.1016/j.atherosclerosis.2011.04.018_bib0360) 2008; 49 Mayne (10.1016/j.atherosclerosis.2011.04.018_bib0445) 2007; 361 Alborn (10.1016/j.atherosclerosis.2011.04.018_bib0330) 2007; 53 Evans (10.1016/j.atherosclerosis.2011.04.018_bib0235) 2006; 7 Dubuc (10.1016/j.atherosclerosis.2011.04.018_bib0100) 2004; 24 Persson (10.1016/j.atherosclerosis.2011.04.018_bib0135) 2009; 150 Brown (10.1016/j.atherosclerosis.2011.04.018_bib0210) 2006; 311 Lakoski (10.1016/j.atherosclerosis.2011.04.018_bib0305) 2009; 94 Jeu (10.1016/j.atherosclerosis.2011.04.018_bib0400) 2003 Kotowski (10.1016/j.atherosclerosis.2011.04.018_bib0225) 2006; 78 Hallman (10.1016/j.atherosclerosis.2011.04.018_bib0215) 2007; 100 Pisciotta (10.1016/j.atherosclerosis.2011.04.018_bib0195) 2005; 186 Cunningham (10.1016/j.atherosclerosis.2011.04.018_bib0025) 2007; 14 Sun (10.1016/j.atherosclerosis.2011.04.018_bib0170) 2005; 14 Schmidt (10.1016/j.atherosclerosis.2011.04.018_bib0290) 2008; 370 Fan (10.1016/j.atherosclerosis.2011.04.018_bib0320) 2008; 47 Kourimate (10.1016/j.atherosclerosis.2011.04.018_bib0125) 2008; 283 |
| References_xml | – volume: 211 start-page: 700 year: 2010 end-page: 702 ident: bib0335 article-title: Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients publication-title: Atherosclerosis contributor: fullname: Langhi – volume: 106 start-page: 9820 year: 2009 end-page: 9825 ident: bib0435 article-title: A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates publication-title: Proc Natl Acad Sci USA contributor: fullname: Cao – volume: 279 start-page: 48865 year: 2004 end-page: 48875 ident: bib0005 article-title: NARC-1/PCSK9 and Its natural mutants: Zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol publication-title: J Biol Chem contributor: fullname: Essalmani – volume: 30 start-page: 520 year: 2009 end-page: 529 ident: bib0155 article-title: Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease publication-title: Hum Mutat contributor: fullname: Devillers – volume: 105 start-page: 1820 year: 2008 end-page: 1825 ident: bib0070 article-title: Molecular basis for LDL receptor recognition by PCSK9 publication-title: Proc Natl Acad Sci USA contributor: fullname: Deisenhofer – volume: 186 start-page: 433 year: 2005 end-page: 440 ident: bib0195 article-title: Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia publication-title: Atherosclerosis contributor: fullname: Cefalu – volume: 354 start-page: 1264 year: 2006 end-page: 1272 ident: bib0200 article-title: Sequence variations in PCSK9, low LDL, and protection against coronary heart disease publication-title: N Engl J Med contributor: fullname: Hobbs – volume: 26 start-page: 1094 year: 2006 end-page: 1100 ident: bib0380 article-title: Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy publication-title: Arterioscler Thromb Vasc Biol contributor: fullname: Leren – volume: 51 start-page: 140 year: 2010 end-page: 149 ident: bib0315 article-title: A new method for measurement of total plasma PCSK9: clinical applications publication-title: J Lipid Res contributor: fullname: Pare – volume: 54 start-page: 1038 year: 2008 end-page: 1045 ident: bib0340 article-title: Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment publication-title: Clin Chem contributor: fullname: Charlton – volume: 206 start-page: 134 year: 2009 end-page: 140 ident: bib0415 article-title: Cellular and secreted pro-protein convertase subtilisin/kexin type 9 catalytic activity in hepatocytes publication-title: Atherosclerosis contributor: fullname: Costet – volume: 34 start-page: 154 year: 2003 end-page: 156 ident: bib0150 article-title: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia publication-title: Nat Genet contributor: fullname: Rabes – volume: 5 start-page: e10682 year: 2010 ident: bib0430 article-title: A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo publication-title: PLoS ONE contributor: fullname: Asselin – volume: 14 start-page: 1161 year: 2005 end-page: 1169 ident: bib0170 article-title: Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia publication-title: Hum Mol Genet contributor: fullname: Tosi – volume: 102 start-page: 2069 year: 2005 end-page: 2074 ident: bib0060 article-title: Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment publication-title: Proc Natl Acad Sci USA contributor: fullname: Breslow – volume: 284 start-page: 10561 year: 2009 end-page: 10570 ident: bib0275 article-title: Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells publication-title: J Biol Chem contributor: fullname: Lagace – volume: 47 start-page: 1631 year: 2008 end-page: 1639 ident: bib0320 article-title: Self-association of human PCSK9 correlates with its LDLR-degrading activity publication-title: Biochemistry contributor: fullname: Qiu – volume: 212 start-page: 246 year: 2010 end-page: 251 ident: bib0365 publication-title: Winkler K. Plasma PCSK9 is increased by Fenofibrate and Atorvastatin in a non additive fashion in diabetic patients contributor: fullname: Guyomarc’h Delasalle – volume: 48 start-page: 763 year: 2007 end-page: 767 ident: bib0425 article-title: Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice publication-title: J Lipid Res contributor: fullname: Whipple – volume: 116 start-page: 2995 year: 2006 end-page: 3005 ident: bib0080 article-title: Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice publication-title: J Clin Invest contributor: fullname: Garuti – volume: 55 start-page: 1637 year: 2009 end-page: 1645 ident: bib0310 article-title: Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents publication-title: Clin Chem contributor: fullname: Tremblay – volume: 2 start-page: e1043 year: 2007 ident: bib0250 article-title: Proprotein convertase subtilisin/kexin type 9 (PCSK9) gene is a risk factor of large-vessel atherosclerosis stroke publication-title: PLoS ONE contributor: fullname: Lutjohann – volume: 25 start-page: 2654 year: 2005 end-page: 2660 ident: bib0180 article-title: Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response publication-title: Arterioscler Thromb Vasc Biol contributor: fullname: Patel – volume: 311 start-page: 1721 year: 2006 end-page: 1723 ident: bib0210 article-title: Lowering LDL—not only how low, but how long? publication-title: Science contributor: fullname: Biomedicine – volume: 113 start-page: 435 year: 2007 end-page: 441 ident: bib0230 article-title: The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men publication-title: Clin Sci (Lond) contributor: fullname: Humphries – volume: 194 start-page: 102 year: 2007 end-page: 111 ident: bib0160 article-title: Genetic defects causing familial hypercholesterolaemia: identification of deletions and duplications in the LDL-receptor gene and summary of all mutations found in patients attending the Hammersmith Hospital Lipid Clinic publication-title: Atherosclerosis contributor: fullname: Soutar – volume: 19 start-page: 949 year: 2008 end-page: 955 ident: bib0120 article-title: Activation of the farnesoid X receptor represses pcsk9 expression in human hepatocytes publication-title: FEBS Lett contributor: fullname: Kourimate – volume: 24 start-page: 1448 year: 2004 end-page: 1453 ident: bib0355 article-title: Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9 publication-title: Arterioscler Thromb Vasc Biol contributor: fullname: Zair – volume: 102 start-page: 5374 year: 2005 end-page: 5379 ident: bib0065 article-title: Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9 publication-title: Proc Natl Acad Sci USA contributor: fullname: Garuti – volume: 7 year: 2008 ident: bib0390 article-title: Plasma PCSK9 levels are significantly modified by statins and fibrates in humans publication-title: Lipids Health Dis contributor: fullname: Raymond – volume: 105 start-page: 11915 year: 2008 end-page: 11920 ident: bib0420 article-title: Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates publication-title: Proc Natl Acad Sci USA contributor: fullname: Anderson – volume: 45 start-page: 1611 year: 2005 end-page: 1619 ident: bib0220 article-title: A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis publication-title: J Am Coll Cardiol contributor: fullname: Marian – volume: 51 start-page: 345 year: 2009 end-page: 351 ident: bib0395 article-title: Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 (PCSK9) levels publication-title: J Lipid Res contributor: fullname: Konrad – volume: 47 start-page: 154 year: 2009 end-page: 158 ident: bib0240 article-title: The PCSK9 gene E670G polymorphism affects low-density lipoprotein cholesterol levels but is not a risk factor for coronary artery disease in ethnic Chinese in Taiwan publication-title: Clin Chem Lab Med contributor: fullname: Ko – volume: 390 start-page: 1288 year: 2009 end-page: 1293 ident: bib0280 article-title: PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion publication-title: Biochem Biophys Res Commun contributor: fullname: Gmyr – volume: 95 start-page: 800 year: 2010 end-page: 809 ident: bib0375 article-title: Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin publication-title: J Clin Endocrinol Metab contributor: fullname: Vega – volume: 420 start-page: 55 year: 2003 end-page: 67 ident: bib0020 article-title: Functional characterization of Narc 1, a novel proteinase related to proteinase K publication-title: Arch Biochem Biophys contributor: fullname: Sreekumar – volume: 26 start-page: 497 year: 2005 ident: bib0190 article-title: Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia publication-title: Hum Mutat contributor: fullname: Abifadel – volume: 24 start-page: 1454 year: 2004 end-page: 1459 ident: bib0100 article-title: Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia publication-title: Arterioscler Thromb Vasc Biol contributor: fullname: Wassef – volume: 48 start-page: 646 year: 2008 end-page: 654 ident: bib0010 article-title: Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration publication-title: Hepatology contributor: fullname: Essalmani – volume: 55 start-page: 2153 year: 2009 end-page: 2161 ident: bib0325 article-title: Healthy individuals carrying the PCSK9 p.R46L variant and familial hypercholesterolemia patients carrying PCSK9 p.D374Y exhibit lower plasma concentrations of PCSK9 publication-title: Clin Chem contributor: fullname: Whittall – volume: 283 start-page: 9666 year: 2008 end-page: 9673 ident: bib0125 article-title: Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9 publication-title: J Biol Chem contributor: fullname: Langhi – volume: 114 start-page: 349 year: 2004 end-page: 353 ident: bib0175 article-title: A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree publication-title: Hum Genet contributor: fullname: Samuels – volume: 213 start-page: 632 year: 2010 end-page: 636 ident: bib0300 article-title: Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population publication-title: Atherosclerosis contributor: fullname: Yang – volume: 44 start-page: 2109 year: 2003 end-page: 2119 ident: bib0105 article-title: Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice publication-title: J Lipid Res contributor: fullname: Breslow – volume: 282 start-page: 20502 year: 2007 end-page: 20512 ident: bib0075 article-title: PCSK9-dependent LDL receptor regulation: effects of pH and LDL publication-title: J Biol Chem contributor: fullname: Pandit – volume: 282 start-page: 20799 year: 2007 end-page: 20803 ident: bib0085 article-title: Catalytic activity is not required for secreted PCSK9 to reduce LDL receptors in HepG2 cells publication-title: J Biol Chem contributor: fullname: Horton – volume: 78 start-page: 410 year: 2006 end-page: 422 ident: bib0225 article-title: A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol publication-title: Am J Hum Genet contributor: fullname: Luke – volume: 7 start-page: 66 year: 2006 ident: bib0235 article-title: The E670G SNP in the PCSK9 gene is associated with polygenic hypercholesterolemia in men but not in women publication-title: BMC Med Genet contributor: fullname: Beil – volume: 53 start-page: 1814 year: 2007 end-page: 1819 ident: bib0330 article-title: Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol publication-title: Clin Chem contributor: fullname: Careskey – year: 2008 ident: bib0095 article-title: Annexin A2 is a C-terminal PCSK9 binding protein that regulates endogenous LDL receptor levels publication-title: J Biol Chem contributor: fullname: Seidah – volume: 370 start-page: 634 year: 2008 end-page: 640 ident: bib0290 article-title: Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo publication-title: Biochem Biophys Res Commun contributor: fullname: Bensch – volume: 150 start-page: 1140 year: 2009 end-page: 1146 ident: bib0135 article-title: Importance of proprotein convertase subtilisin/kexin type 9 in the hormonal and dietary regulation of rat liver low-density lipoprotein receptors publication-title: Endocrinology contributor: fullname: Rudling – start-page: 2352 year: 2003 end-page: 2387 ident: bib0400 article-title: Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor publication-title: Clin Ther contributor: fullname: Cheng – volume: 79 start-page: 514 year: 2006 end-page: 523 ident: bib0270 article-title: Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote publication-title: Am J Hum Genet contributor: fullname: Lagace – volume: 49 start-page: 394 year: 2008 end-page: 398 ident: bib0360 article-title: Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9 publication-title: J Lipid Res contributor: fullname: Konrad – volume: 195 start-page: e19 year: 2007 end-page: e27 ident: bib0255 article-title: Molecular diagnosis of hypobetalipoproteinemia: an ENID review publication-title: Atherosclerosis contributor: fullname: Di – volume: 283 start-page: 2363 year: 2008 end-page: 2372 ident: bib0040 article-title: The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2 publication-title: J Biol Chem contributor: fullname: Benjannet – volume: 2 start-page: 354 year: 2009 end-page: 361 ident: bib0205 article-title: Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels: the Coronary Artery Risk Development in Young Adults Study publication-title: Circ Cardiovasc Genet contributor: fullname: Liu – volume: 584 start-page: 701 year: 2009 end-page: 706 ident: bib0410 article-title: PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities publication-title: FEBS Lett contributor: fullname: Mayne – volume: 49 start-page: 1303 year: 2008 end-page: 1311 ident: bib0285 article-title: Plasma PCSK9 preferentially reduces liver LDL receptors in mice publication-title: J Lipid Res contributor: fullname: Horton – volume: 53 start-page: 513 year: 2010 ident: bib0295 article-title: Loss of the association between plasma pro-protein convertase subtilisin/kexin type 9 (PCSK9) and LDL-apoB100 catabolism in type 2 diabetes publication-title: Poster. Diabetologia contributor: fullname: Cariou – volume: 375 start-page: 69 year: 2008 end-page: 73 ident: bib0045 article-title: PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide publication-title: Biochem Biophys Res Commun contributor: fullname: Hedrick – volume: 55 start-page: 2049 year: 2009 end-page: 2052 ident: bib0345 article-title: Plasma proprotein convertase subtilisin/kexin type 9: a marker of LDL apolipoprotein B-100 catabolism? publication-title: Clin Chem contributor: fullname: Watts – volume: 282 start-page: 18602 year: 2007 end-page: 18612 ident: bib0050 article-title: Binding of PCSK9 to EGF-A repeat of LDL receptor decreases receptor recycling and increases degradation publication-title: J Biol Chem contributor: fullname: Garuti – year: 2010 ident: bib0440 article-title: A proprotein convertase subtilisin-like/kexin type 9 (PCSK9)-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces free circulating PCSK9 and LDL-cholesterol publication-title: J Lipid Res contributor: fullname: Condra – volume: 361 start-page: 451 year: 2007 end-page: 456 ident: bib0445 article-title: Plasma PCSK9 levels correlate with cholesterol in men but not in women publication-title: Biochem Biophys Res Commun contributor: fullname: Chaplin – volume: 406 start-page: 203 year: 2007 end-page: 207 ident: bib0090 article-title: Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity publication-title: Biochem J contributor: fullname: Gavigan – volume: 100 start-page: 69 year: 2007 end-page: 72 ident: bib0215 article-title: Relation of PCSK9 mutations to serum low-density lipoprotein cholesterol in childhood and adulthood (from The Bogalusa Heart Study) publication-title: Am J Cardiol contributor: fullname: Berenson – volume: 12 start-page: 752 year: 2010 end-page: 756 ident: bib0385 article-title: Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients publication-title: Diabetes Obes Metab contributor: fullname: Rye – volume: 51 start-page: 2714 year: 2010 end-page: 2721 ident: bib0370 article-title: High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol publication-title: J Lipid Res contributor: fullname: Konrad – volume: 29 start-page: 684 year: 2009 end-page: 690 ident: bib0015 article-title: Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia publication-title: Arterioscler Thromb Vasc Biol contributor: fullname: Langhi – volume: 27 start-page: 677 year: 2007 end-page: 681 ident: bib0265 article-title: A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol publication-title: Arterioscler Thromb Vasc Biol contributor: fullname: Di – volume: 284 start-page: 28885 year: 2009 end-page: 28895 ident: bib0110 article-title: Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine publication-title: J Biol Chem contributor: fullname: Liu – volume: 208 start-page: 177 year: 2010 end-page: 182 ident: bib0245 article-title: Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles publication-title: Atherosclerosis contributor: fullname: Grigore – volume: 29 start-page: 2191 year: 2009 end-page: 2197 ident: bib0260 article-title: PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia publication-title: Arterioscler Thromb Vasc Biol contributor: fullname: Zair – volume: 147 start-page: 4985 year: 2006 end-page: 4995 ident: bib0350 article-title: Fasting induces hyperlipidemia in mice overexpressing PCSK9: lack of modulation of VLDL hepatic output by the LDLr publication-title: Endocrinology contributor: fullname: Pineau – volume: 31 start-page: 785 year: 2011 end-page: 791 ident: bib0055 article-title: Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue publication-title: Arterioscler Thromb Vasc Biol contributor: fullname: Awan – volume: 30 start-page: 2666 year: 2010 end-page: 2672 ident: bib0130 article-title: Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans publication-title: Arterioscler Thromb Vasc Biol contributor: fullname: Stahle – volume: 51 start-page: 3359 year: 2010 end-page: 3363 ident: bib0140 article-title: Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans publication-title: J Lipid Res contributor: fullname: Horton – volume: 43 start-page: 943 year: 2006 end-page: 949 ident: bib0185 article-title: Genetic causes of Familial Hypercholesterolaemia in UK patients: relation to plasma lipid levels and coronary heart disease risk publication-title: J Med Genet contributor: fullname: Hubbart – volume: 94 start-page: 2537 year: 2009 end-page: 2543 ident: bib0305 article-title: Genetic and metabolic determinants of plasma PCSK9 levels publication-title: J Clin Endocrinol Metab contributor: fullname: Hobbs – volume: 14 start-page: 413 year: 2007 end-page: 419 ident: bib0025 article-title: Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia publication-title: Nat Struct Mol Biol contributor: fullname: Geoghegan – volume: 104 start-page: 14604 year: 2007 end-page: 14609 ident: bib0030 article-title: The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain publication-title: Proc Natl Acad Sci USA contributor: fullname: Spraggon – volume: 293 start-page: E737 year: 2007 end-page: E742 ident: bib0145 article-title: Age-induced hypercholesterolemia in the rat relates to reduced elimination but not increased intestinal absorption of cholesterol publication-title: Am J Physiol Endocrinol Metab contributor: fullname: Rudling – volume: 281 start-page: 6211 year: 2006 end-page: 6218 ident: bib0115 article-title: Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory-element binding protein 1c publication-title: J Biol Chem contributor: fullname: Lambert – volume: 15 start-page: 545 year: 2007 end-page: 552 ident: bib0035 article-title: The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol publication-title: Structure contributor: fullname: Liu – volume: 31 start-page: E1811 year: 2010 end-page: E1824 ident: bib0165 article-title: Molecular spectrum of autosomal dominant hypercholesterolemia in France publication-title: Hum Mutat contributor: fullname: Sassolas – volume: 470 start-page: 111 year: 2008 end-page: 115 ident: bib0405 article-title: Diabetes alters LDL receptor and PCSK9 expression in rat liver publication-title: Arch Biochem Biophys contributor: fullname: Lopez – volume: 30 start-page: 520 issue: April (4) year: 2009 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0155 article-title: Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease publication-title: Hum Mutat doi: 10.1002/humu.20882 contributor: fullname: Abifadel – volume: 283 start-page: 2363 issue: January (4) year: 2008 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0040 article-title: The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2 publication-title: J Biol Chem doi: 10.1074/jbc.M708098200 contributor: fullname: Poirier – volume: 14 start-page: 1161 issue: May (9) year: 2005 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0170 article-title: Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia publication-title: Hum Mol Genet doi: 10.1093/hmg/ddi128 contributor: fullname: Sun – volume: 470 start-page: 111 issue: February (2) year: 2008 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0405 article-title: Diabetes alters LDL receptor and PCSK9 expression in rat liver publication-title: Arch Biochem Biophys doi: 10.1016/j.abb.2007.11.009 contributor: fullname: Niesen – volume: 49 start-page: 1303 issue: March (6) year: 2008 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0285 article-title: Plasma PCSK9 preferentially reduces liver LDL receptors in mice publication-title: J Lipid Res doi: 10.1194/jlr.M800027-JLR200 contributor: fullname: Grefhorst – start-page: 2352 issue: September (9) year: 2003 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0400 article-title: Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor publication-title: Clin Ther doi: 10.1016/S0149-2918(03)80281-3 contributor: fullname: Jeu – volume: 311 start-page: 1721 issue: March (5768) year: 2006 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0210 article-title: Lowering LDL—not only how low, but how long? publication-title: Science doi: 10.1126/science.1125884 contributor: fullname: Brown – volume: 282 start-page: 20799 issue: May (29) year: 2007 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0085 article-title: Catalytic activity is not required for secreted PCSK9 to reduce LDL receptors in HepG2 cells publication-title: J Biol Chem doi: 10.1074/jbc.C700095200 contributor: fullname: McNutt – volume: 5 start-page: e10682 issue: 5 year: 2010 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0430 article-title: A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo publication-title: PLoS ONE doi: 10.1371/journal.pone.0010682 contributor: fullname: Gupta – volume: 279 start-page: 48865 issue: November (47) year: 2004 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0005 article-title: NARC-1/PCSK9 and Its natural mutants: Zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol publication-title: J Biol Chem doi: 10.1074/jbc.M409699200 contributor: fullname: Benjannet – issue: September year: 2008 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0095 article-title: Annexin A2 is a C-terminal PCSK9 binding protein that regulates endogenous LDL receptor levels publication-title: J Biol Chem contributor: fullname: Mayer – volume: 420 start-page: 55 issue: December (1) year: 2003 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0020 article-title: Functional characterization of Narc 1, a novel proteinase related to proteinase K publication-title: Arch Biochem Biophys doi: 10.1016/j.abb.2003.09.011 contributor: fullname: Naureckiene – volume: 361 start-page: 451 issue: September 21 year: 2007 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0445 article-title: Plasma PCSK9 levels correlate with cholesterol in men but not in women publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2007.07.029 contributor: fullname: Mayne – volume: 105 start-page: 11915 issue: August (33) year: 2008 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0420 article-title: Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0805434105 contributor: fullname: Frank-Kamenetsky – volume: 51 start-page: 2714 issue: September (9) year: 2010 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0370 article-title: High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol publication-title: J Lipid Res doi: 10.1194/jlr.M008144 contributor: fullname: Welder – volume: 48 start-page: 763 issue: April (4) year: 2007 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0425 article-title: Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice publication-title: J Lipid Res doi: 10.1194/jlr.C600025-JLR200 contributor: fullname: Graham – volume: 26 start-page: 1094 issue: May (5) year: 2006 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0380 article-title: Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/01.ATV.0000204337.81286.1c contributor: fullname: Berge – volume: 19 start-page: 949 issue: February (582(6)) year: 2008 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0120 article-title: Activation of the farnesoid X receptor represses pcsk9 expression in human hepatocytes publication-title: FEBS Lett doi: 10.1016/j.febslet.2008.02.038 contributor: fullname: Langhi – volume: 15 start-page: 545 issue: May (5) year: 2007 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0035 article-title: The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol publication-title: Structure doi: 10.1016/j.str.2007.04.004 contributor: fullname: Piper – volume: 12 start-page: 752 issue: September (9) year: 2010 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0385 article-title: Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients publication-title: Diabetes Obes Metab doi: 10.1111/j.1463-1326.2010.01229.x contributor: fullname: Chan – volume: 102 start-page: 2069 issue: February (6) year: 2005 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0060 article-title: Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0409736102 contributor: fullname: Maxwell – volume: 29 start-page: 684 issue: May (5) year: 2009 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0015 article-title: Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/ATVBAHA.108.181586 contributor: fullname: Le May – volume: 113 start-page: 435 issue: December (11) year: 2007 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0230 article-title: The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men publication-title: Clin Sci (Lond) doi: 10.1042/CS20070150 contributor: fullname: Scartezini – volume: 147 start-page: 4985 issue: June (10) year: 2006 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0350 article-title: Fasting induces hyperlipidemia in mice overexpressing PCSK9: lack of modulation of VLDL hepatic output by the LDLr publication-title: Endocrinology doi: 10.1210/en.2006-0098 contributor: fullname: Lambert – volume: 186 start-page: 433 issue: September (2) year: 2005 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0195 article-title: Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia publication-title: Atherosclerosis contributor: fullname: Pisciotta – volume: 212 start-page: 246 issue: September (1) year: 2010 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0365 publication-title: Winkler K. Plasma PCSK9 is increased by Fenofibrate and Atorvastatin in a non additive fashion in diabetic patients contributor: fullname: Costet – volume: 370 start-page: 634 issue: April (4) year: 2008 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0290 article-title: Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2008.04.004 contributor: fullname: Schmidt – volume: 105 start-page: 1820 issue: February (6) year: 2008 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0070 article-title: Molecular basis for LDL receptor recognition by PCSK9 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0712064105 contributor: fullname: Kwon – volume: 53 start-page: 513 issue: supplt 1 year: 2010 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0295 article-title: Loss of the association between plasma pro-protein convertase subtilisin/kexin type 9 (PCSK9) and LDL-apoB100 catabolism in type 2 diabetes publication-title: Poster. Diabetologia contributor: fullname: Verges – volume: 51 start-page: 3359 issue: November (11) year: 2010 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0140 article-title: Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans publication-title: J Lipid Res doi: 10.1194/jlr.P009860 contributor: fullname: Browning – volume: 284 start-page: 28885 issue: October (42) year: 2009 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0110 article-title: Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine publication-title: J Biol Chem doi: 10.1074/jbc.M109.052407 contributor: fullname: Li – volume: 45 start-page: 1611 issue: May (10) year: 2005 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0220 article-title: A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2005.01.051 contributor: fullname: Chen – volume: 55 start-page: 2049 issue: November (11) year: 2009 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0345 article-title: Plasma proprotein convertase subtilisin/kexin type 9: a marker of LDL apolipoprotein B-100 catabolism? publication-title: Clin Chem doi: 10.1373/clinchem.2009.128645 contributor: fullname: Chan – volume: 2 start-page: e1043 issue: 10 year: 2007 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0250 article-title: Proprotein convertase subtilisin/kexin type 9 (PCSK9) gene is a risk factor of large-vessel atherosclerosis stroke publication-title: PLoS ONE doi: 10.1371/journal.pone.0001043 contributor: fullname: Abboud – volume: 49 start-page: 394 issue: February (2) year: 2008 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0360 article-title: Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9 publication-title: J Lipid Res doi: 10.1194/jlr.M700437-JLR200 contributor: fullname: Careskey – volume: 282 start-page: 18602 issue: April (25) year: 2007 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0050 article-title: Binding of PCSK9 to EGF-A repeat of LDL receptor decreases receptor recycling and increases degradation publication-title: J Biol Chem doi: 10.1074/jbc.M702027200 contributor: fullname: Zhang – volume: 79 start-page: 514 issue: September (3) year: 2006 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0270 article-title: Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote publication-title: Am J Hum Genet doi: 10.1086/507488 contributor: fullname: Zhao – volume: 14 start-page: 413 issue: May (5) year: 2007 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0025 article-title: Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia publication-title: Nat Struct Mol Biol doi: 10.1038/nsmb1235 contributor: fullname: Cunningham – volume: 106 start-page: 9820 issue: May (24) year: 2009 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0435 article-title: A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0903849106 contributor: fullname: Chan – volume: 293 start-page: E737 issue: September (3) year: 2007 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0145 article-title: Age-induced hypercholesterolemia in the rat relates to reduced elimination but not increased intestinal absorption of cholesterol publication-title: Am J Physiol Endocrinol Metab doi: 10.1152/ajpendo.00166.2007 contributor: fullname: Galman – volume: 78 start-page: 410 issue: March (3) year: 2006 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0225 article-title: A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol publication-title: Am J Hum Genet doi: 10.1086/500615 contributor: fullname: Kotowski – volume: 51 start-page: 345 issue: September (2) year: 2009 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0395 article-title: Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 (PCSK9) levels publication-title: J Lipid Res contributor: fullname: Troutt – volume: 44 start-page: 2109 issue: November (11) year: 2003 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0105 article-title: Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice publication-title: J Lipid Res doi: 10.1194/jlr.M300203-JLR200 contributor: fullname: Maxwell – volume: 206 start-page: 134 issue: September (1) year: 2009 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0415 article-title: Cellular and secreted pro-protein convertase subtilisin/kexin type 9 catalytic activity in hepatocytes publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2009.02.012 contributor: fullname: Kourimate – volume: 354 start-page: 1264 issue: March (12) year: 2006 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0200 article-title: Sequence variations in PCSK9, low LDL, and protection against coronary heart disease publication-title: N Engl J Med doi: 10.1056/NEJMoa054013 contributor: fullname: Cohen – volume: 195 start-page: e19 issue: December (2) year: 2007 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0255 article-title: Molecular diagnosis of hypobetalipoproteinemia: an ENID review publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2007.05.003 contributor: fullname: Tarugi – volume: 150 start-page: 1140 issue: March (3) year: 2009 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0135 article-title: Importance of proprotein convertase subtilisin/kexin type 9 in the hormonal and dietary regulation of rat liver low-density lipoprotein receptors publication-title: Endocrinology doi: 10.1210/en.2008-1281 contributor: fullname: Persson – volume: 7 year: 2008 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0390 article-title: Plasma PCSK9 levels are significantly modified by statins and fibrates in humans publication-title: Lipids Health Dis doi: 10.1186/1476-511X-7-22 contributor: fullname: Mayne – volume: 114 start-page: 349 issue: March (4) year: 2004 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0175 article-title: A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree publication-title: Hum Genet doi: 10.1007/s00439-003-1071-9 contributor: fullname: Timms – issue: October year: 2010 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0440 article-title: A proprotein convertase subtilisin-like/kexin type 9 (PCSK9)-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces free circulating PCSK9 and LDL-cholesterol publication-title: J Lipid Res contributor: fullname: Ni – volume: 283 start-page: 9666 issue: February (15) year: 2008 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0125 article-title: Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9 publication-title: J Biol Chem doi: 10.1074/jbc.M705831200 contributor: fullname: Kourimate – volume: 24 start-page: 1448 issue: August (8) year: 2004 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0355 article-title: Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9 publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/01.ATV.0000133684.77013.88 contributor: fullname: Ouguerram – volume: 43 start-page: 943 issue: June (12) year: 2006 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0185 article-title: Genetic causes of Familial Hypercholesterolaemia in UK patients: relation to plasma lipid levels and coronary heart disease risk publication-title: J Med Genet doi: 10.1136/jmg.2006.038356 contributor: fullname: Humphries – volume: 406 start-page: 203 issue: September (2) year: 2007 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0090 article-title: Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity publication-title: Biochem J doi: 10.1042/BJ20070664 contributor: fullname: Li – volume: 29 start-page: 2191 issue: December (12) year: 2009 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0260 article-title: PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/ATVBAHA.109.194191 contributor: fullname: Cariou – volume: 34 start-page: 154 issue: June (2) year: 2003 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0150 article-title: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia publication-title: Nat Genet doi: 10.1038/ng1161 contributor: fullname: Abifadel – volume: 53 start-page: 1814 issue: October (10) year: 2007 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0330 article-title: Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol publication-title: Clin Chem doi: 10.1373/clinchem.2007.091280 contributor: fullname: Alborn – volume: 48 start-page: 646 issue: August (2) year: 2008 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0010 article-title: Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration publication-title: Hepatology doi: 10.1002/hep.22354 contributor: fullname: Zaid – volume: 31 start-page: E1811 issue: November (11) year: 2010 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0165 article-title: Molecular spectrum of autosomal dominant hypercholesterolemia in France publication-title: Hum Mutat doi: 10.1002/humu.21348 contributor: fullname: Marduel – volume: 55 start-page: 2153 issue: December (12) year: 2009 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0325 article-title: Healthy individuals carrying the PCSK9 p.R46L variant and familial hypercholesterolemia patients carrying PCSK9 p.D374Y exhibit lower plasma concentrations of PCSK9 publication-title: Clin Chem doi: 10.1373/clinchem.2009.129759 contributor: fullname: Humphries – volume: 7 start-page: 66 year: 2006 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0235 article-title: The E670G SNP in the PCSK9 gene is associated with polygenic hypercholesterolemia in men but not in women publication-title: BMC Med Genet doi: 10.1186/1471-2350-7-66 contributor: fullname: Evans – volume: 194 start-page: 102 issue: September (1) year: 2007 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0160 article-title: Genetic defects causing familial hypercholesterolaemia: identification of deletions and duplications in the LDL-receptor gene and summary of all mutations found in patients attending the Hammersmith Hospital Lipid Clinic publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2006.10.003 contributor: fullname: Tosi – volume: 104 start-page: 14604 issue: September (37) year: 2007 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0030 article-title: The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0703402104 contributor: fullname: Hampton – volume: 211 start-page: 700 issue: August (2) year: 2010 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0335 article-title: Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2010.04.015 contributor: fullname: Cariou – volume: 94 start-page: 2537 issue: July (7) year: 2009 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0305 article-title: Genetic and metabolic determinants of plasma PCSK9 levels publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2009-0141 contributor: fullname: Lakoski – volume: 116 start-page: 2995 issue: November (11) year: 2006 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0080 article-title: Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice publication-title: J Clin Invest doi: 10.1172/JCI29383 contributor: fullname: Lagace – volume: 51 start-page: 140 issue: January (1) year: 2010 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0315 article-title: A new method for measurement of total plasma PCSK9: clinical applications publication-title: J Lipid Res doi: 10.1194/jlr.M900273-JLR200 contributor: fullname: Dubuc – volume: 390 start-page: 1288 issue: October (4) year: 2009 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0280 article-title: PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2009.10.138 contributor: fullname: Langhi – volume: 47 start-page: 1631 issue: February (6) year: 2008 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0320 article-title: Self-association of human PCSK9 correlates with its LDLR-degrading activity publication-title: Biochemistry doi: 10.1021/bi7016359 contributor: fullname: Fan – volume: 54 start-page: 1038 issue: June (6) year: 2008 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0340 article-title: Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment publication-title: Clin Chem doi: 10.1373/clinchem.2007.099747 contributor: fullname: Lambert – volume: 25 start-page: 2654 issue: December (12) year: 2005 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0180 article-title: Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/01.ATV.0000190668.94752.ab contributor: fullname: Naoumova – volume: 100 start-page: 69 issue: July (1) year: 2007 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0215 article-title: Relation of PCSK9 mutations to serum low-density lipoprotein cholesterol in childhood and adulthood (from The Bogalusa Heart Study) publication-title: Am J Cardiol doi: 10.1016/j.amjcard.2007.02.057 contributor: fullname: Hallman – volume: 282 start-page: 20502 issue: May (28) year: 2007 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0075 article-title: PCSK9-dependent LDL receptor regulation: effects of pH and LDL publication-title: J Biol Chem doi: 10.1074/jbc.M701634200 contributor: fullname: Fisher – volume: 2 start-page: 354 issue: August (4) year: 2009 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0205 article-title: Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels: the Coronary Artery Risk Development in Young Adults Study publication-title: Circ Cardiovasc Genet doi: 10.1161/CIRCGENETICS.108.828467 contributor: fullname: Huang – volume: 47 start-page: 154 issue: 2 year: 2009 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0240 article-title: The PCSK9 gene E670G polymorphism affects low-density lipoprotein cholesterol levels but is not a risk factor for coronary artery disease in ethnic Chinese in Taiwan publication-title: Clin Chem Lab Med doi: 10.1515/CCLM.2009.032 contributor: fullname: Hsu – volume: 208 start-page: 177 issue: January (1) year: 2010 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0245 article-title: Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2009.06.023 contributor: fullname: Norata – volume: 55 start-page: 1637 issue: July (9) year: 2009 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0310 article-title: Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents publication-title: Clin Chem doi: 10.1373/clinchem.2009.126987 contributor: fullname: Baass – volume: 24 start-page: 1454 issue: August (8) year: 2004 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0100 article-title: Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/01.ATV.0000134621.14315.43 contributor: fullname: Dubuc – volume: 375 start-page: 69 issue: October (1) year: 2008 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0045 article-title: PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2008.07.106 contributor: fullname: Shan – volume: 27 start-page: 677 issue: March (3) year: 2007 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0265 article-title: A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/01.ATV.0000255311.26383.2f contributor: fullname: Fasano – volume: 584 start-page: 701 issue: December (4) year: 2009 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0410 article-title: PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities publication-title: FEBS Lett contributor: fullname: Mbikay – volume: 26 start-page: 497 issue: November (5) year: 2005 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0190 article-title: Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia publication-title: Hum Mutat doi: 10.1002/humu.9383 contributor: fullname: Allard – volume: 281 start-page: 6211 issue: January (10) year: 2006 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0115 article-title: Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory-element binding protein 1c publication-title: J Biol Chem doi: 10.1074/jbc.M508582200 contributor: fullname: Costet – volume: 31 start-page: 785 issue: April (1) year: 2011 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0055 article-title: Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/ATVBAHA.110.220988 contributor: fullname: Roubtsova – volume: 102 start-page: 5374 issue: April (15) year: 2005 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0065 article-title: Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0501652102 contributor: fullname: Rashid – volume: 30 start-page: 2666 issue: December (1) year: 2010 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0130 article-title: Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/ATVBAHA.110.214130 contributor: fullname: Persson – volume: 213 start-page: 632 issue: December (2) year: 2010 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0300 article-title: Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2010.09.027 contributor: fullname: Cui – volume: 95 start-page: 800 issue: February (2) year: 2010 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0375 article-title: Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2009-1952 contributor: fullname: Lakoski – volume: 284 start-page: 10561 issue: April (16) year: 2009 ident: 10.1016/j.atherosclerosis.2011.04.018_bib0275 article-title: Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells publication-title: J Biol Chem doi: 10.1074/jbc.M808802200 contributor: fullname: McNutt |
| SSID | ssj0004718 |
| Score | 2.4364438 |
| SecondaryResourceType | review_article |
| Snippet | Abstract Proprotein convertase subtilisin kexin type 9 (PCSK9) is a circulating protein that impairs LDL clearance by promoting the LDL receptor (LDLR)... Proprotein convertase subtilisin kexin type 9 (PCSK9) is a circulating protein that impairs LDL clearance by promoting the LDL receptor (LDLR) degradation.... |
| SourceID | hal proquest crossref pubmed pascalfrancis elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 258 |
| SubjectTerms | Adolescent Animals Atherosclerosis (general aspects, experimental research) Azetidines - therapeutic use Biological and medical sciences Blood and lymphatic vessels Cardiology and cardiovascular system Cardiology. Vascular system Cardiovascular Clinical trial. Drug monitoring Diabetes Mellitus, Type 2 - blood Endocrinology and metabolism Ezetimibe Female Fibric Acids - therapeutic use General pharmacology Genes, Dominant Human health and pathology Humans Hypercholesterolemia Hypercholesterolemia - blood Hépatology and Gastroenterology LDL Life Sciences Lipid Metabolism Lipoprotein Male Medical sciences Mice Mutation Nutritional Status PCSK9 Pharmacology. Drug treatments Phenotype Proprotein Convertase 9 Proprotein Convertases Protease Inhibitors - pharmacology Receptors, LDL - metabolism Serine Endopeptidases - blood Statin Tissues and Organs |
| Title | Clinical aspects of PCSK9 |
| URI | https://www.clinicalkey.es/playcontent/1-s2.0-S0021915011003601 https://dx.doi.org/10.1016/j.atherosclerosis.2011.04.018 https://www.ncbi.nlm.nih.gov/pubmed/21596380 https://search.proquest.com/docview/871003109 https://hal.science/hal-03013330 |
| Volume | 216 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS-QwEB90BTmQQ0_P6925lMN7rDZN26RvtyzK-ongCb6FpJvgyrG72NVH__abadNd_AJBCn1Im6aZyUx-k8xMAHZlUqSltiISNuERSiKPirxIoiE3ZiiFy3i9e352ng-u0uPr7HoJ-m0sDLlVet3f6PRaW_uSfU_N_eloRDG-KG2IZyjpGc8phmsFp6NEdmCld3QyOF-ERwrWKGTyRsAKq_B74eZV46xJhV_F-6jyST3TvZiOAXl9qlq-IZ_JtamukIyuOf_ibYBaT1SH6_DZI8yw13RiA5bs-Ausnvk99E0IfCrQf6GuwyyrcOLCi_7lSbEFV4cHf_uDyB-QEJUI42aRS6wzOndxlnEhyoTr1MiyQBvEMG6dkC63ZRo7xrVDKFfilTmXm3hoHNNogn6Fzngytt8gNPRUsjJhOiWTsuDENy2HNhMmFTKAvKWFmjZ5MFTrIHarnhFRERFVnCokYgCipZxqgz1RPdnKy0qlmKoSFasX_Azgz7zmkyGhUNu_t_FfyKv5D1Mq7UHvVFEZmYKc8_gB2-k-YeX8dUQvkvG8CCBseatQ-GhHRY_t5L5SknIjUW7VALYbni8qI05E3RZ__3gvfsCnZiWb1n5-Qmd2d293EArNTBeW9x5Z1w_4_0RVBdI |
| link.rule.ids | 230,315,783,787,888,4509,24128,27936,27937,45597,45691 |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3rS-QwEB98gAoid-c9qp6WQz_2bJu2Sb-5LCfVfXCggt9C0k1wj2N3sev9_c606S6-QDgK_ZA2TTOTmfwmmZkAHIs4T0pleMBNzAKURBbkWR4HI6b1SHCbsnr3fDDMipvk8ja9XYFuGwtDbpVO9zc6vdbWruTUUfN0Nh5TjC9KG-IZSnrGMorhWkc0kKN0rncuesVwGR7Jo0YhkzcCVtiAk6WbV42zphV-Fe_jyiX1TH6GdAzI61PV6h35TG7PVIVktM35F28D1HqiOv8AOw5h-p2mEx9hxUw-wcbA7aHvgudSgf71VR1mWflT6__uXvXyz3Bz_uu6WwTugISgRBg3D2xsrFaZDdOUcV7GTCValDnaIDpixnJhM1MmoY2YsgjlSrxSazMdjrSNFJqgX2BtMp2Yb-BreiqiMo5UQiZlzohvSoxMynXChQdZSws5a_JgyNZB7I98RkRJRJRhIpGIHvCWcrIN9kT1ZConK5WMZBXLUL7gpwdni5pPhoREbf_exn8grxY_TKm0i05fUhmZgoyx8B-2c_iElYvXEb2IiGW5B37LW4nCRzsqamKmD5UUlBuJcqt68LXh-bIy4kTUbeHe__fiCDaL60Ff9i-GvX3Yala1aR3oANbm9w_mO8KiuT50w_4RmGwHxg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+aspects+of+PCSK9&rft.jtitle=Atherosclerosis&rft.au=Cariou%2C+Bertrand&rft.au=Le+May%2C+C%C3%A9dric&rft.au=Costet%2C+Philippe&rft.date=2011-06-01&rft.eissn=1879-1484&rft.volume=216&rft.issue=2&rft.spage=258&rft.epage=265&rft_id=info:doi/10.1016%2Fj.atherosclerosis.2011.04.018&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F00219150%2FS0021915011X00060%2Fcov150h.gif |